Clinical Trial Update: Tisagenlecleucel In Primary CNS Lymphoma [Phase 1]

View source ↗

Summary

This update covers a Phase 1 study of tisagenlecleucel in primary central nervous system lymphoma, including refractory/relapsed cases, which has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• tisagenlecleucel (Kymriah) (tisagenlecleucel)

Snippet

Sponsor: Matthew J. Frigault, M.D. | Conditions: Primary CNS Lymphoma, Refractory Primary CNS Lymphoma | Phase 1 | Status: COMPLETED